摘要
首先扼要地介绍了子宫移植从动物实验转化到临床试验的状况;然后分析了子宫移植的受益以及子宫移植及相关治疗措施对供体、受体和未来孩子的可能风险,讨论对风险-受益比的评估,有效知情同意的获得以及相关的其他伦理问题;最后分析子宫移植的监管和治理问题,并指出了子宫移植从临床试验转化为临床应用的条件。
This article first briefly describes the translation from animal experiments into clinical trials in the development of uterus transplantation. Then it identifies the benefits from uterus transplantation and risks from surgical operations and treatments involved in uterus transplantation to donor, recipient and future child, and discusses the risk-benefit ratio assessment, valid informed consent to be obtained, and other related ethical issues. Finally the article discusses regulatory and governance issues, and suggests the conditions under which clinical trials could be translated into clinical application.
作者
雷瑞鹏
邱仁宗
LEI Ruipeng;QIU Renzong(School of Humanities,Huazhong University of Science and Technology,Wuhan 430074,China;Institute of Philosophy,Chinese Academy of SocialSciences,Beijing 100732,China)
出处
《中国医学伦理学》
2019年第6期689-694,共6页
Chinese Medical Ethics
关键词
子宫移植
子宫因素不孕
风险-受益比
有效的知情同意
公平可及
Uterus Transplantation
Uterus Factor Infertility
Risk-Benefit Ratio
Valid Informed Consent
Equitable Access